The new approvals bring the number of denosumab biosimilars in the US to eight, but price reductions are not yet substantial.
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback